Scangas George A, Eloy Jean Anderson, Lin Derrick T
Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, 243 Charles Street, Boston, MA 02114, USA.
Endoscopic Skull Base Surgery Program, Department of Otolaryngology - Head and Neck Surgery, Rhinology and Sinus Surgery, Otolaryngology Research, Neurological Institute of New Jersey, Rutgers New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103, USA.
Otolaryngol Clin North Am. 2017 Apr;50(2):433-441. doi: 10.1016/j.otc.2016.12.015. Epub 2017 Feb 1.
In most cases of advanced sinonasal and ventral skull base cancer, a multimodal treatment approach provides the best chance for improved outcomes. Depending on the tumor type and extent of disease, systemic chemotherapy has been shown to play an important role in neoadjuvant, concomitant, and adjuvant settings. The lack of randomized trials continues to limit its indications. Further high-quality studies are needed to understand ideal chemotherapeutic regimens and their role and sequential timing in sinonasal and ventral skull base cancer.
在大多数晚期鼻窦和颅底腹侧癌病例中，多模式治疗方法为改善预后提供了最佳机会。根据肿瘤类型和疾病范围，全身化疗已被证明在新辅助、同步和辅助治疗中发挥重要作用。缺乏随机试验继续限制了其适应证。需要进一步的高质量研究来了解鼻窦和颅底腹侧癌的理想化疗方案及其作用和序贯时机。
